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Abstract 
Thyroid hormone receptors play a crucial role in regulating differentiation, growth and 
development in response to thyroid hormone, and mutations in these receptors can have severe 
medical consequences ranging from endocrine dysfunction to cancer. Tumors of patients with 
hepatocellular carcinoma (HCC) display a high incidence of mutant thyroid hormone receptors 
(TRs), and one such mutant is TRα1 (K74E, A264V). The binding partners and gene targets of 
this mutant have been characterized, but the role of intracellular localization in the pathogenesis 
of TRα1 (K74E, A264V) has not yet been determined. Here, it was observed that the mutant 
receptor has a tendency to aggregate when transfected into HeLa (human) cells. Fluorescence 
microscopy was used to determine the extent of this aggregation. The data showed that the TR 
mutant displays a significantly higher frequency of nuclear and cytosolic aggregates. 
Furthermore, it induces a significantly higher amount of nuclear and cytosolic aggregates in the 
wild type TR when coexpressed in the cell, and this effect increases with increasing amounts of 
transfected mutant-containing plasmid. These results highlight a potential dominant-negative of 
TRα1 (K74E, A264V) effect as it pertains to localization and offer a new layer of understanding 
to the altered activity of this mutant TR during the development of cancer.  
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Introduction 
Big Picture 
The goal of this honors thesis is to look at a cancerous thyroid hormone receptor from a different 
angle, specifically where it is located within the cell. The localization of a protein is instrumental 
in its ability to carry out its physiological function, and altered localization can lead to pathology 
(Hung and Link, 2011). To understand the significance of this research, it is first important to 
understand the details on thyroid hormone receptor’s function, its mechanism, its link to cancer 
and the mutant studied in this thesis, and how localization can play into the cancerous phenotype.  
 
Thyroid Hormone  
The story of thyroid hormone receptors begins with the genesis of thyroid hormone, regulated by 
the hypothalamic-pituitary axis in the brain (Mullur et al., 2014). The initial signal to increase 
thyroid hormone production comes from the secretion of thyrotropin-releasing hormone (TRH) 
by the hypothalamus. TRH acts on the pituitary gland to induce secretion of thyroid stimulating 
hormone (TSH). TSH then acts on the thyroid gland to stimulate the production and release of 
thyroid hormone in the forms of T3 and T4, with the three and the four referring to the number of 
iodine groups the hormone contains (Figure 1). The thyroid produces the longer-lived T4 in 
higher quantities than T3, though T3 is considered to be the more active form of thyroid hormone. 
T4 is converted to T3 locally at or in the target tissue through deiodinases D1 and D2 or to the 
more inactive reverse T3 (rT3) (Dentice et al., 2013). When the thyroid hormone enters a target 
cell, through specific transporters such as monocarboxylate transporter 8 (MCT8), organic anion-
transporting polypeptide 1C1 (OATP1C1), or other related transporters, it can interact with its 
receptor (Visser et al., 2011). 
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             Figure 1: Structure of thyroid hormone 
Thyroid Hormone Receptors 
Structure 
Thyroid hormone receptors (TRs) are nuclear receptors which act as transcription factors, 
modulating gene expression based on ligand binding. Humans have two TR genes, THRA and 
THRB, which are differentially expressed based on tissue type and stage in development 
(Pascual and Aranda, 2013). Each gene encodes multiple distinct receptors through differential 
RNA splicing (Figure 2). THRA encodes one T3-binding splice variant, TRα1, and two non-T3-
binding splice variants, TRα2 and TRα3, along with several other truncated forms. THRB codes 
for three major T3-binding splice products, TRβ1, TRβ2, and TRβ3. All of these variations on the 
TR theme are part of the reason why thyroid hormone can have selective actions on certain cell 
types. The basic structure of TR and of nuclear receptors in general involves four broad domains 
(Figure 3). The first domain is an amino-terminal “A/B” domain which recruits coregulatory 
proteins (Rosen and Privalsky, 2011).  This domain also contains a nuclear localization signal 
(NLS), named NLS-2, in TRα1, which allows for the import of the TR into the nucleus through 
the nuclear pore complex. (Mavinakere et al., 2012). The second domain is the “C” domain, or 
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the DNA-binding domain (DBD) where the receptor can interact with specific nucleotide 
sequences in the genome. The “D” domain is the third domain, and it is also known as the hinge 
region, acting as a flexible link that joins the “C” and the “E/F” domains. In TRα1 and TRβ1, the 
hinge region also contains an NLS known as NLS-1 (Mavinakere et al. 2012; Lee and Mahdavi, 
1993). The last domain, a carboxyl-terminal ligand-binding domain (LBD) also known as the 
“E/F” domain, is where ligands such as T3 can bind and induce conformational changes in the 
rest of the protein to alter the receptor’s activity. Additionally, this site forms a receptor 
dimerization surface, acts as a major site for coregulatory interaction, and contains multiple 
nuclear export signals (NESs), (NES-H12), (NES-H3), and (NES-H6), named for the helical 
structures on which they reside (Mavinakere et al., 2012). The NESs allow for TR shuttling out 
of the nucleus. 
 
Figure 2: Major TR splice variants (modified from Ortiga-Carvalho et al. 2014). 
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Figure 3: General layout of the TR domains. Not drawn to scale. 
 
Mechanism of Action 
TRs act as dimers, either binding to different nuclear receptors such as retinoid acid receptor 
(RXR) in a heterodimer or to other TRs in a homodimer (Brent, 2012) (Figure 4). The dimer 
binds to DNA sequences known as T3 response elements (TREs) and regulates the expression of 
associated genes in response to thyroid hormone by recruiting coactivators when up-regulating 
gene expression or corepressors when down-regulating gene expression. TRs not bound to T3 
have a repressive effect on genes positively regulated by T3 and an activating effect on genes 
normally repressed by T3. TRs accumulate in the nucleus, though they rapidly shuttle in and out 
via importins and exportins (Bunn et al., 2001; Subramanian et al., 2015; Roggero et al., 2016).  
 
 
5 
 
 
   Figure 4: TR mechanism of action (modified from Brent, 2012). 
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Thyroid Hormone Receptors and Cancer 
Oncogenesis 
The link between thyroid hormone receptors and cancer was first established in chickens infected 
with avian erythroblastoma virus (AEV). One of the viral genes that contributed to oncogenic 
(cancerous) transformation was a highly mutated TRα1 ortholog, v-ErbA (Thormeyer and 
Baniahmad, 1999). The key mutations involved in differentiating oncogenic TRs from normally 
functioning ones are found in two domains, the DNA-binding domain and the ligand binding 
domain. When there is a significant mutation in the DNA binding domain, not only will the TRs 
bind to a subset of their usual TREs, but they also acquire, and therefore misregulate, new gene 
targets which could promote neoplasia (Rosen and Privalsky, 2011). TRs have a role in tumor 
suppression, and losing that role also promotes tumorigenesis (Wu et al., 2013; Zhu et al., 2010). 
Significant mutations in the ligand-binding domain could either prevent or hamper T3 binding to 
block the protein’s ability to “sense” the levels of ligand within the cell. In these cases, not only 
can the TR not activate genes positively regulated by T3 and repress genes negatively regulated 
by T3, but it also continuously silences or activates genes, which should be regulated this way in 
the absence of T3, even when thyroid hormone is present in abundance. Furthermore, loss of 
function can occur when there is a normally functioning wild-type TR counterpart. The mutant 
TR will display dominant-negative activity, competing with the wild type for TRE binding and 
preventing the normal regulatory activity of the wild type TR (Kim and Cheng, 2013). This two-
pronged attack to normal cellular functioning is a trademark of oncogenic TRs.  
 
 
 
7 
 
 
Hepatocellular Carcinoma and TRα1 (K74E, A264V) 
Liver cancer such as hepatocellular carcinoma (HCC) is the fifth most common cancer 
worldwide and the third most common cause of cancer mortality (El-Serag et al., 2007). HCC is 
most commonly linked with cirrhosis, and the major risk factor involved is hepatitis B and C 
viral infection. Interestingly, TRs with point mutations were detected with high frequency in 
human HCC tumors (Lin et al., 1999).  TRα1 (K74E, A264V) is one such TR implicated in HCC 
is the focus of this research, displaying mutations in the typical areas leading to oncogenicity 
(Figure 5). The lysine at position 74 is a conserved residue in the DNA-binding domain which 
acts as an allosteric sensor, regulating transcriptional activity in response to DNA binding (Chan 
and Privalsky, 2010). In this mutant, the positively-charged lysine is exchanged for the 
negatively-charged glutamate, effecting a substantial conformational shift in a crucial area of the 
protein. This causes the mutant to display an altered target gene repertoire leading to the 
misregulation of tumor suppressor genes, oncogenes, and genes involved with cell migration and 
metastasis (Chan and Privalsky, 2009). Additionally, the alanine at position 264 in the ligand-
binding domain is mutated to the bulkier valine, resulting in a delayed corepressor release and 
reduced sensitivity to T3 (Rosen and Privalsky, 2011). 
 
Figure 5: TRα1 (K74E, A264V) 
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Localization 
This thesis starts at the intersection of cancer and localization. The second mutation in TRα1 
(K74E, A264V) is in NES H3/H6 (spanning amino acid residues 209-265), making it of interest 
for localization studies (Mavinakere et al., 2012).  Previous research has shown that the 
oncoprotein v-ErbA is mislocalized; much of v-ErbA remains cytoplasmic due in part to an 
acquired viral NES (DeLong, et al., 2004). Furthermore, it displays a dominant-negative activity 
in that it binds to TRα and sequesters a significant fraction in the cytoplasm thus preventing wild 
type TRα from binding TRE unlike conventional TRE competition (Bonamy et al., 2005). 
Consequently, localization can play a large role in the oncogenic actions of mutant TRs.  
 
Research Aims 
This thesis explored whether TRα1 (K74E, A264V) is mislocalized within the cell relative to 
wild type TRα1, and if so, whether the mislocalization has a dominant-negative effect on wild 
type TRα1. 
 
Materials and Methods 
Plasmids 
GFP-TRα1 and the mCherry-TRα1 expression plasmids were previously described (Bunn et al., 
2001; Bondzi et al., 2011). The TRα1 (K74E, A264V) parent plasmid was obtained through 
GeneArt. GFP-TRα1 (K74E, A264V) was prepared by subcloning the TRα1 (K74E, A264V) 
cDNA into a GFP vector, and mCherry-TRα1(K74E, A264V) was prepared by subcloning the 
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TRα1(K74E, A264V) coding region from GFP-TRα1(K74E, A264V) into mCherry 
C1(Clontech). 
 
Cell Culture and Transfections 
HeLa cells (human cervical epithelioid carcinoma) were grown and maintained at 37°C and 5% 
CO2 in Minimum Essential Medium (Gibco), supplemented with 10% fetal bovine serum 
(Invitrogen). For each transfection, 2.5 x 10
5
 HeLa cells were seeded into each well of a 6-well 
plate with glass coverslips (Fisher) and incubated at 37°C for approximately 24 hrs. Various 
amounts of plasmid expression vectors were introduced using Lipofectamine 2000 (Invitrogen) 
according to the manufacturer’s recommendations (Appendix A). Cells were fixed 24 - 28 hrs 
post-transfection and analyzed by fluorescence microscopy. 
 
Fixation and Staining 
Cells were fixed approximately 24-28 hrs post-transfection. After aspirating off the media, each 
well was washed with 2mL 1X D-PBS solution in 3 rounds of 15-second washes (Appendix B). 
The cells were then fixed with a solution of 2mL 3.7% formaldehyde for 10 minutes. This was 
followed by 3 washes of 2mL 1X D-PBS for 2 minutes each. Coverslips were then mounted onto 
microscope slides in Fluoro-Gel II (Electron Microscopy Sciences) containing the DNA stain 
DAPI (4, 6-diamino-2-phenylindole). 
 
Phenotypic Categorization and Statistical Analysis. 
Images were collected from an inverted Nikon ECLIPSE TE 2000-E fluorescent microscope 
(Sigma, Melville, NY) using a 40X objective lens and acquired using NIS-Elements AR software 
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(Nikon). The filters used to visualize localization patterns were the UV-2E/C filter block for the 
DAPI, the FITC (blue light) B-2E/C filter block for GFP, and the TRITC (green light) T-2E/C 
filter block for the mCherry.   
 
Before the slides were analyzed, they were blinded by another lab member to control for bias. At 
least four replicate trials were performed, with a minimum of two slides per replicate and 200 
cells categorized per slide averaged out for each replicate. Results were tested for statistical 
significance using a Student’s T-test, and a p-value of less than 0.05 was considered to be 
significant. 
 
Results  
TRα1 (K74E, A264V) forms significantly more aggregates than its wild type counterpart 
Previous research has indicated that an altered localization (including association with 
aggresomes) could contribute to the oncogenic properties of v-ErbA (Bondzi et al., 2011), 
therefore a similar approach was taken with the mutant TRα1 (K74E, A264V). In order to 
visualize this protein, two GFP expression vectors were used to fluorescently tag the mutant and 
the wild type TRα1. HeLa cells were transfected with either 2μg of the wild type or the mutant 
plasmid, fixed, stained, and then viewed under a fluorescent microscope. After preliminary 
analysis of the mutant TR cellular distribution, a high incidence of protein aggregation was 
noted. This is in direct contrast with the fairly consistently even distribution of the wild-type TR. 
Therefore, in order to quantify the significance of this deviation from normal distribution, a 
count of the varying phenotypes was conducted. Three main phenotypes were defined as 
categories for scoring (Figure 6). “Nuclear aggregates” describes cells which have aggregates 
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clearly in the nucleus either by fluorescent delineation or by overlap with the DNA stain DAPI. 
“Cytosolic aggregates” encompasses a whole cell distribution of aggregates or covering a range 
greater than that demarcated by the DAPI stain. Finally, “even” refers to a lack of significant 
aggregates in that cell. After five trials of categorizing cells (n=200), the wild type cells 
displayed an average of 196.7 out of 200even-distribution cells, 0.1 cells with nuclear 
aggregates, and 2.9 cells with cytosolic aggregates (Figure 7). The mutant, on the other hand, 
showed an average of 154 cells out of 200 with an even distribution, 27.2 cells with nuclear 
aggregates, and 18.8 cells with cytosolic aggregates.  
  
Figure 6: Categories of phenotypes for GFP-TRα1 (K74E, A264V) (green). The nucleus is shown in blue 
(DAPI stain). A) Even distribution B) Nuclear aggregates C) Cytosolic aggregates.  
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Figure 7: Quantitative comparison of wild type TRα1 and mutant TRα1 (K74E, A264V) cellular 
distributions. Bars indicate standard error of the mean (SEM). 
 
The differences between the wild type and the mutant were analyzed using a Student’s T-test, 
generating p-values of 3.07e-6, 0.004, and 0.002 for the categories of even distribution, nuclear 
aggregates, and cytosolic aggregates, respectively. 
 
Aggregation indicates a high level of misfolded proteins within the cell. Aggregates are 
commonly nonhomogeneous and may contain chaperone molecules, proteasome subunits, 
glycosaminoglycans (GAGs), and proteoglycans other than the specific insoluble proteins 
(Bartolini and Andrisano, 2010). The recruited molecules appear to promote aggregate formation 
and reduce its clearance. Aggregates can pose problems for cells, mediating toxicity and 
impeding normal cellular functions. Nuclear aggregates were rarely seen in the cells transfected 
with wild type TRα1, and this may be a method of regulating nuclear retention of TRα1 (K74E, 
A264V). It could be a cellular way to prevent DNA binding while chaperones and proteasomes 
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work to bring down the level of misfolded protein in the nucleus. Alternatively aggregates can 
act as rapidly reforming and restructuring entities, so it is possible mutant TRs in the nucleus 
could switch between DNA-binding to fusion with aggregates (Fu et al., 2005). Cytosolic 
aggregates could also sequester the mutant TR in the cytoplasm, preventing transcriptional 
regulation. 
 
As a qualitative observation, the cells with GFP- TRα1 (K74E, A264V) distributing evenly 
throughout the cell appeared to have a reduced fluorescence in contrast to the bright fluorescence 
seen in cells displaying aggregates. This might indicate a threshold level of expression before 
significant aggregate formation. On the other hand, this could simply be the result of a 
concentration of otherwise diffuse fluorescent molecules. The punctate nature of the aggregates 
makes quantification of relative fluorescent intensity more of a challenge.  
 
 
Wild type TRα1 displays nuclear and cytosolic aggregates when coexpressed with TRα1 
(K74E, A264V) 
After demonstrating that TRα1 (K74E, A264V) forms aggregates, the next step was to ascertain 
whether the mutant TR aggregates could interfere with the localization of wild type TRα1. In 
order to do this, mCherry-TRα1 plasmids were used to distinguish the wild type TR when it was 
co-transfected with the GFP-TRα1 (K74E, A264V) plasmid. Cells were transfected with 2μg of 
wild type DNA alone, 2μg of mutant DNA alone, or 1μg of wild type DNA and 1μg of mutant 
DNA simultaneously. The same categories were used as before, and it was determined that the 
wild type TR exhibited altered localization when coexpressed with the mutant (Figure 8). When 
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expressed alone in the cell, mCherry-TRα1 had an average of 196.6 out of 200 cells with an even 
distribution, 0.9 cells with nuclear aggregates, and 2.5 cells with cytosolic aggregates (Figure 9). 
When coexpressed with GFP- TRα1 (K74E, A264V), mCherry-TRα1 had an average of 181.9 
cells with an even distribution, 12.1 cells with nuclear aggregates, and 5.4 cells with cytosolic 
aggregates. Differences between the two conditions were once again analyzed using a Student’s 
t-test, yielding p-values of 7.78e-05, 8.92e-05, and 0.09 for the categories of even distribution, 
nuclear aggregates, and cytosolic aggregates, respectively.  This demonstrates that the number of 
cells with evenly distributed wild type TRs and cells with wild type TRs aggregating in the 
nucleus were significantly different between the control and the co-transfected groups.  
15 
 
 
Fi
gu
re
 8
: P
h
en
o
ty
p
ic
 c
at
eg
o
ri
es
 u
se
d
 f
o
r 
q
u
an
ti
fy
in
g 
co
tr
an
sf
ec
ti
o
n
 a
gg
re
ga
ti
o
n
. 
16 
 
  
Figure 9: Cotransfection trials. Bars indicate SEM. 
 
To ensure that the aggregation of mCherry-TRα1 was not due to aberrant mutant activity within 
the cell, the differences between GFP- TRα1 (K74E, A264V) expressed alone and with 
mCherry-TRα1were analyzed as a control (Figure 10). When only GFP-TRα1 (K74E, A264V) 
was transfected, an average of 158.9, 16.6, and 24 out of 200 cells displayed an even distribution, 
nuclear aggregates, and cytosolic aggregates respectively. When GFP-TRα1 (K74E, A264V) was 
co-transfected with mCherry-TRα1, an average of 176.9, 9.5, and 13.6 out of 200 cells presented 
an even distribution, nuclear aggregates, and cytosolic aggregates respectively. Using Student’s 
t-test, p-values of 0.04 for the even distribution, 0.19 for nuclear aggregates, and 0.05 for 
cytosolic aggregates were obtained. Transfection of mutant TR resulted in significantly more 
cells with an even distribution and significantly less cells with cytosolic aggregates when co-
transfected with the wild type TR (using 1μg of mutant plasmid DNA), in contrast with the 
0
20
40
60
80
100
120
140
160
180
200
Even Nuclear
Aggregates
Cytoplasmic
Aggregates
N
u
m
b
er
 o
f 
C
el
ls
 
Cellular Phenotype 
Cotransfection of TRα1 and TRα1 (K74E, 
A264V)  
mCherry-TRα1 
mCherry-TRα1 with GFP-TRα1 
(K74E, A264V) 
* 
  Cytosolic 
N.S 
* 
17 
 
mutant TR transfected alone using 2μg of plasmid DNA. There was no significant difference 
between the two conditions for nuclear aggregates. As there was no increase in mutant 
aggregates in the co-transfected cells, it is unlikely to have affected the significance of the 
previous analysis.  
 
Figure 10: Control analysis of GFP-TRα1 (K74E, A264V) alone and with mCherry-TRα1. Bars indicate 
SEM. 
 
These results suggest that TRα1 (K74E, A264V) could be sequestering wild type TRα1 in these 
aggregates, whether in the cytosol or in the nucleus. This would add an additional means to 
dominant negative action by the mutant TR, comparable to v-ErbA (Bondzi et al., 2011). 
 
Increased expression of TRα1 (K74E, A264V) increases wild type aggregation 
The next step was to determine whether the dominant-negative action of TRα1 (K74E, A264V) 
would increase upon increased expression. The same expression vectors were used, but with 3μg 
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of wild type DNA, 3μg or mutant DNA, and for the cotransfection, 1μg of wild type DNA per 
2μg of mutant DNA. Preliminary analysis determined that a new phenotypic category needed to 
be added for scoring. In addition to the previous aggregate distribution, a significant number of 
cells displayed “perinuclear” aggregates where the aggregates are neither strictly within the 
bounds of the nucleus nor are they spread throughout the cell (Figure 11). Instead, these 
aggregates encompass the nuclear region delineated via fluorescence or DAPI along with the 
cytoplasm directly near and around the nucleus. Cells were quantified using these four categories 
(Figure 12). Wild type TR expressed alone presented an average of 197.5, 0.9, 0.4, and 1.2 out of 
200 cells with an even distribution, nuclear aggregates, perinuclear aggregates, and cytosolic 
aggregates respectively. Wild type TR expressed with twice the amount of mutant TR displayed 
an average of 154.4, 19.4, 15.9, and 10.4 out of 200 cells with an even distribution, nuclear 
aggregates, perinuclear aggregates, and cytosolic aggregates respectively. The same statistical 
test was used to yield p-values of 0.003 for the even distribution, 0.016 for the nuclear 
aggregates, 0.002 for the perinuclear aggregates, and 0.048 for the cytosolic aggregates. Even 
with the additional category for describing the aggregate phenotypes, the wild type TR showed 
nuclear, perinuclear, and cytosolic aggregates significantly more when co-transfected with the 
mutant TR than when transfected alone.  Wild type TR distributed significantly less evenly in the 
presence of the increased expression of mutant TR as well. Furthermore the percentage of cells 
with wild type TR aggregates shows a clear increase from a 1:1 to a 1:2 wild type to mutant co-
expression, indicating that the dominant-negative effect increases with increasing amounts of 
mutant TR. 
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Figure 11: Perinuclear aggregates. A) Merged image B) DAPI C) GFP- TRα1 (K74E, A264V) 
D) mCherry- TRα1 
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Figure 12: Analysis of the phenotypes of wild type TR in cells transfected with an increase of TRα1 (K74E, 
A264V) plasmid. Bars indicate SEM. 
 
 
 
Figure 13: Analysis of GFP-TRα1 (K74E, A264V) as a control to the analysis of wild type distribution in 
response to an increase in mutant plasmid. Bars indicate SEM.  
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As before, the behavior of the mutant expressed with and without the wild type TR was also 
analyzed (Figure 13). Cells expressing only GFP-TRα1 (K74E, A264V) had 138.1 out of 200 
cells with an even distribution, 16.6 cells with nuclear aggregates, 18 cells with perinuclear 
aggregates, and 27.3 cells with cytosolic aggregates on average. Cells expressing GFP- TRα1 
(K74E, A264V) with mCherry-TRα1 exhibited an average of 136.5 out of 200 cells with an even 
distribution, 15.5 cells with nuclear aggregates, 16.95 cells with perinuclear aggregates, and 
29.125 cells with cytosolic aggregates. P-values of 0.85, 0.71, 0.71, and 0.77 were obtained for 
the categories of even distribution, nuclear aggregates, perinuclear aggregates, and cytosolic 
aggregates respectively, indicating no significant differences between the mutant TR co-
transfected with the wild type and the mutant TR transfected alone. Therefore the differences 
between wild type distributions under the previously described conditions were not likely to have 
been affected by an abnormal increase in aggregation from the co-transfected mutants. 
 
The high frequency of perinuclear aggregation could indicate the beginnings of aggresome 
formation within the cell. Aggresomes are a cellular response to misfolded proteins linked to 
cancer and neurodegenerative diseases (Johnston et al., 1998). The viral oncogenic TR, v-ErbA, 
displays dynamic trafficking to aggresomes, contributing to its dominant negative activity 
(Bondzi et al. 2011). While the specific foci associated with aggresomes were seen less 
frequently, longer periods of mutant expression could allow time for the coalescing of the 
individual aggregates into aggresomes. Aggresomes are further characterized by recruitment of 
chaperones and proteasomes and the breakdown and restructuring of the cytoskeletal protein 
vimentin that area (Johnston et al., 1998). Without these additional verification methods, the 
presence of aggresomes cannot be confirmed. Nevertheless, these data provide additional support 
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for the potential of dominant-negative sequestration of wild-type TR into aggregates by TRα1 
(K74E, A264V). 
 
Discussion 
TRα1 (K74E, A264V) displays nuclear and cytosolic aggregation 
Previously, investigations into the HCC mutant TRα1 (K74E, A264V) have focused on its 
altered target gene repertoire and its decreased sensitivity to T3 (Chan and Privalsky, 2009; Chan 
and Privalsky, 2010). Studies using the model oncogenic TR, v-ErbA, have introduced new ways 
in which mutant TRs can impede normal cellular functioning, notably through mislocalization 
and aggregate formation (Bonamy et al., 2006). These experiments determined that TRα1 
(K74E, A264V) displays an altered localization by way of aggregate formation and a capability 
to induce wild type TRα1 aggregate formation. 
 
Protein aggregation is a process in which monomer peptides or proteins self-associate into non-
native and less soluble structures (Bartolini and Andrisano, 2010). Aggregates are generally 
associated with misfolded proteins, so the significant levels of aggregation in the mutant TR 
suggest one or both of the mutations may have changed the conformation of either or both of the 
mutation-containing domains. This could increase the likelihood of overall misfolding within the 
cell. Given the often complete aggregation within cells shown here, misfolded TRs might 
interact with other TRs to promote further misfolding. Additional research needs to be conducted 
to expound the mechanisms mediating nuclear and cytosolic aggregation and the potential 
significance of this process in cancer cells in vivo. 
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One question which arises from these results is whether the localization of the nuclear aggregates 
is random or more directed. GFP 170*, a nuclear aggregate forming protein, is known to alter the 
organization of subnuclear domains containing the promyelocytic leukemia protein (PML) 
proteins known as PML bodies (Fu et al, 2005). Subnuclear domains are part of the 
organizational structure of the nucleus, providing centers of ribosome biogenesis in the 
nucleolus, RNA splicing in nuclear speckles, nuclear retention of specific RNA molecules which 
can associate with the nucleolus in paraspeckles, potential regulation of splicing machinery 
components in Cajal bodies, and potential RNA metabolism in PML bodies (Mitrea and 
Kriwacki, 2016; Spector and Lamond, 2011; Fox et al., 2002). The specific and full range of 
function for most of these remains unknown. Preliminary studies were designed to determine 
potential colocalization with the previously characterized nuclear aggregate forming GFP 170*, 
though the results only showed a modest correlation which could simply be indicative of the 
largely nuclear localization shared between the two proteins. Therefore, the question of whether 
the aggregates formed by the mutant TR also localize to and affect the architecture of subnuclear 
domains such as PML bodies has yet to be determined.  
 
TRα1 (K74E, A264V) induces aggregate formation in TRα1  
TRα1 generally distributes evenly with a mostly nuclear distribution. When expressed with 
TRα1 (K74E, A264V), a significant portion of the cells displayed visible aggregates above the 
background distribution of fluorescence. This phenotype increases with increased amounts of 
TRα1 (K74E, A264V)-containing plasmid, providing strong evidence that the mutant directly 
effects this behavior in its wild type counterpart. This is significant because each cell has two 
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copies of the THRA gene, so dominant-negative activity of the mutant TR will likewise affect 
the wild type TR in vivo. 
 
Sequestration of wild type TR in aggregates may contribute to the dominant-negative activity of 
TRα1 (K74E, A264V). Although the induced aggregates would appear to colocalize with the 
mutant aggregates, the epifluorescent microscope can only give two-dimensional images. 
Though it is unlikely, fluorescent proteins aggregates that appear to coincide may simply be 
along the same z-axis. Therefore, other methods such as confocal microscopy would be needed 
to verify the colocalization suggested in this study. 
 
The oncogenic TR model, v-ErbA, was shown to sequester a subset of TRα in aggresomes 
(Bondzi et al., 2011), so with the formation of aggregates in TRα1 (K74E, A264V), there is a 
question of whether aggresomes will form under certain conditions and whether that could also 
play a role in the pathogenesis of this mutant. Aggregates may coalesce to form aggresomes 
through motor-dependent movement on microtubules (Fu et al. 2005). The formation of a 
cytosolic aggresome is associated with the collapse of the intermediate filament vimentin, 
involved with the cytoskeletal structure of the cell. Aggresomes have foci near the nucleus at 
centrosomes, and vimentin forms a cytoskeletal cage around them to contain the misfolded 
proteins and mitigate the toxic effect on normal cell functioning. Chaperones and proteases are 
recruited to the structure, though it remains unclear whether aggresomes are cytoprotective in 
that deleterious proteins are sequestered or pathogenic as they are frequently associated with 
disease (Bondzi et al. 2011). Although the increase of perinuclear aggregates with the 
transfection of increased amounts of mutant TR plasmid could potentially indicate the result of 
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microtubule-dependent movement of aggregates towards the centrosomes, all of these cellular 
events would need to be investigated before the confirmation of this structure. The role of 
aggresomes in v-ErbA pathogenesis has been determined, but thus far any relevance to TRα1 
(K74E, A264V) is purely speculative. 
 
Future Directions  
Initial results strongly support the partial colocalization of TRα1 with TRα1 (K74E, A264V) 
aggregates, and they merit a more sophisticated method of analysis with tools such as confocal 
microscopy or fluorescence resonance energy transfer (FRET). Confocal microscopy can reveal 
the three-dimensional structure of a specimen, selectively collecting light from a thin optical 
section at the plane of focus so that no out-of-focus fluorescence from different depths within the 
cell interferes with the image (Smith, 2008). With confocal microscopy, overlap of fluorescence 
at an exact point on a focal plane would be more easily seen and therefore colocalization would 
be more easily determined. FRET is a distance-dependent physical process in which an excited 
fluorophore (the donor) transfers energy to another fluorophore (the acceptor) (Sekar and 
Periasamy, 2003). During the transfer, some energy is lost, and the fluorescence emitted is of a 
different wavelength and therefore a different color than what would be emitted from the donor 
fluorophore. Interactions between proteins can be measured if one protein is labeled with a donor 
fluorophore and the other is labeled with an acceptor fluorophore. When a FRET event occurs, 
the fluorescent intensity of the donor will be reduced and that of the acceptor will be increased; 
measuring these signal changes could allow for the measurement of colocalization between 
proteins such as TRα1 and TRα1 (K74E, A264V) within aggregates. 
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In order to examine whether TRα1 (K74E, A264V)  localizes to a subnuclear domain,  proteins 
characteristic of certain nuclear domains, such as PML protein for PML bodies, could be 
immunostained and then analyzed for colocalization with the GFP-tagged mutant. Confocal 
microscopy, or another method for colocalization analysis, would suit this effort as well. 
Additionally, the domain protein and TRα1 (K74E, A264V) could be labeled with a 
donor/acceptor pair for FRET. These methods would provide more definitive answers as to 
whether there are specific foci for nuclear aggregate formation. 
 
Furthermore, to explore whether potential sequestration of TRα1 in aggresomes is a factor in 
HCC, conditions could be altered to promote aggresome formation. Allowing for increasing 
amounts time of between transfection and fixation could promote a greater degree of 
microtubule-dependent of aggregates into aggresomes. Additionally, as HCC frequently 
develops from cirrhotic livers, cells could be exposed to similar kinds of stressors that would 
better replicate conditions in HCC tumors. To further approach in vivo behavior, it may be more 
beneficial to use hepatocytes for these studies. This can be paired with visualization via 
immunostaining (using fluorescently-labeled antibodies specific for the protein of interest) the 
mutant TR as opposed to overexpression studies, using gene editing to introduce the needed 
mutations. This would ensure that any resulting altered localization occurs under normal 
expression levels and is not simply due to an excess of protein. Using these additional measures 
could better elucidate how TRα1 (K74E, A264V) behaves in the cancerous liver. 
 
Results from these studies will spark new questions and bring new answers to advance the 
understanding of the many ways TRα1 (K74E, A264V)  interferes with normal cellular 
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functioning to promote oncogenesis, paving the way for better treatment options for individuals 
with HCC and other cancers involving mutant TRs. 
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Appendix A. 
Transfection Protocol  
After the cells have been trypsinized, add 15 μl of the cell suspension to a hemacytometer 
to determine the cell number, and add  ~2.5 x10
5
 cells per well to a 6-well plate with glass 
coverslips. Incubate the cells at 37°C for ~24 hours. 
In a biosafety cabinet, dilute target amount of plasmid DNA with Opti-MEM (reduced 
serum media) for a total volume of 250 μl in 6 separate tubes. In a different tube, add 1476 μl 
Opti-MEM, then add 24 μl for a total volume of 1500 μl. Incubate the solutions for 5 minutes at 
room temperature. 
Add 250 μl Lipofectamine-Opti-MEM to each of the DNA-Opti-MEM solutions for a 
total volume of 500 μl. Mix gently then let the solution to sit at room temperature for 20 minutes 
to allow formation of DNA-liposome complexes. 
Add the DNA-liposome complexes to each of the prepared wells. Mix gently, and 
incubate the cells plus complexes for 6-8 hours at 37°C.  
Replace the medium with fresh, complete medium. 
 
 
Appendix B 
D-PBS 
KCl 0.10 g 
KH2PO4 0.10 g 
NaCl 4.00 g 
Na2HPO4•7H2O 1.08 g 
Add ddH2O to 500ml, autoclave, and store at room temperature. 
  
 
